Two-dimensional shear wave elastography (2D-SWE) is a non-invasive imaging technique used to measure liver stiffness, which helps assess the severity of liver fibrosis. Liver fibrosis occurs when scar tissue builds up in the liver, often due to conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), a liver condition linked to obesity and metabolic issues.
Two-dimensional shear wave elastography (2D-SWE) is a non-invasive imaging technique used to measure liver stiffness, which helps assess the severity of liver fibrosis. Liver fibrosis occurs when scar tissue builds up in the liver, often due to conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), a liver condition linked to obesity and metabolic issues. Early detection of fibrosis is critical, as advanced stages (like cirrhosis) increase the risk of complications such as liver failure or cancer.
2D-SWE works by sending ultrasound waves into the liver and measuring how quickly shear waves travel through the tissue. Stiffer liver tissue, often caused by fibrosis, results in faster wave propagation. This method is gaining attention because it provides accurate, reproducible results and is relatively easy to perform.
In MASLD, 2D-SWE is particularly useful because it overcomes some limitations of older techniques like vibration-controlled transient elastography (VCTE), which can be less accurate in obese patients. A recent meta-analysis has established standardized cutoff values for 2D-SWE to improve its diagnostic accuracy for different stages of fibrosis. By integrating 2D-SWE into clinical practice, healthcare providers can better identify high-risk MASLD patients, enabling earlier interventions and improved management of liver health.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.